Skip to main content
. 2012 Dec 22;7(5):838–846. doi: 10.1111/irv.12071

Table 1.

The number of samples and the seroprevalence obtained for each age‐group at each time point during and after the pandemic

Age‐group Months
6–7/2009 8–9/2009 10–11/2009 12/09–1/10 2–3/2010 4–5/2010 6–7/2010 8–9/2010
0–9 years
n 60 60 60 129 95 116 100 100
% Positivea 0 11·7 (3·5–19·8) 16·7 (7·2–26·1) 46·5 (37·9–55·1) 54·7 (44·7–64·8) 43·1 (34·1–52·1) 45·0 (35·3–54·8) 40·0 (30·4–49·6)
GMTb 10·1 (9·9–10·3) 13·3 (11·0–16·2) 15·3 (11·9–19·6) 32·1 (25·4–40·5) 54·7 (38·7–77·5) 31·3 (24·6–39·8) 31·4 (24·2–40·6) 27·7 (21·5–35·7)
10–19 Years
n 60 60 60 168 110 141 100 108
% Positivea 15·0 (5·9–24·0) 18·3 (8·5–28·1) 33·3 (21·4–45·3) 44·0 (36·5–51·6) 60·9 (51·8–70·0) 59·6 (51·5–67·7) 65·0 (55·7–74·4) 57·4 (48·1–66·7)
GMTb 15·7 (12·1–20·3) 14·5 (12·1–17·2) 26·4 (18·8–37·0) 37·4 (29·8–47·0) 56·9 (42·3–76·6) 54·5 (42·2–70·3) 55·0 (42·1–71·9) 50·7 (38·1–67·5)
20–49 Years
n 178 177 169 200 186 243 296 292
% Positivea 7·9 (3·9–11·8) 10·2 (5·7–14·6) 14·2 (8·9–19·5) 31·5 (25·1–37·9) 30·1 (23·5–36·7) 21·8 (16·6–27·0) 28·4 (23·2–33·5) 26·4 (21·3–31·4)
GMTb 12·2 (11·1–13·5) 13·5 (12·0–15·2) 14·3 (12·8–16·1) 22·2 (18·7–26·3) 24·9 (20·5–30·3) 18·7 (16·3–21·5) 20·7 (18·1–23·7) 18·7 (16·8–20·9)
50–79 Years
n 174 179 176 195 216 257 256 248
% Positivea 4·0 (1·1–6·9) 7·3 (3·5–11·1) 8·5 (4·4–12·7) 16·9 (11·7–22·2) 20·8 (15·4–26·3) 19·1 (14·3–23·9) 15·6 (11·2–20·1) 10·5 (6·7–14·3)
GMTb 11·1 (10·6–11·7) 12·1 (11·2–13·0) 13·1 (12·0–14·3) 15·8 (13·8–18·0) 18·3 (15·7–21·2) 16·3 (14·4–18·4) 14·4 (13·2–15·9) 13·6 (12·5–14·9)
80 Years+
n 28 24 35 35 41 43 48 52
% Positivea 21·4 (6·2–36·6) 41·7 (21·9–61·4) 42·9 (26·5–59·3) 45·7 (29·2–62·2) 46·3 (31·8–61·6) 53·5 (38·6–68·4) 39·6 (25·8–53·4) 32·7 (19·9–45·4)
GMTb 16·8 (12·3–22·9) 22·2 (14·4–34·3) 22·5 (16·6–30·5) 28·6 (18·9–43·1) 35·5 (25·0–50·5) 36·3 (24·6–53·6) 27·5 (19·8–38·2) 21·7 (16·4–28·6)
a

Data are % (95% confidence interval).

b

Geometric mean titer (95% confidence interval).